Be the first to like this
The bio-pharmaceutical industry has been rather slow in embracing Big Data Analytics due to its inherent costs, difficulty in measuring ROI of Big Data, uneven senior management buy-in and other challenges associated with harnessing large sets of information in varied formats. As the industry moves towards recognizing the huge potential that BIG DATA holds for important HEOR decisions, rapid steps are being taken to develop greater BIG DATA capabilities.
Best Practices, LLC undertook this study to probe current & future trends, winning strategies and best practices for Big Data utilization across the HEOR function. The study lprobes the most useful data types and sources for key HEOR decisions; governance policies and leadership and the most meaningful data producers, dissemination channels and targets.
Download Full Report: http://bit.ly/2byZH9g